The 17th International Winter Eicosanoid Conference
Eicosanoid Research Association, Inc.
We gratefully acknowledge the following Institutions
for their support
of the 17th International Winter
Pharmaceuticals Holdings, Inc. is a development stage pharmaceutical company
focused on the development and commercialization of novel therapeutics to treat
rare, chronic, and serious inflammatory and fibrotic diseases. The Company’s
lead product candidate, lenabasum, is a novel, synthetic oral
endocannabinoid-mimetic drug designed to resolve chronic inflammation and
fibrotic processes. Lenabasum is currently being evaluated in systemic
sclerosis, cystic fibrosis, dermatomyositis, and systemic lupus erythematosus.
Prostaglandins and Other Lipid Mediators
New York Medical College